title: [Poliomyelitis in New Caledonia: epidemiological data, post-vaccinal seroconversion, prophylactic strategy].
abstract: After an outbreak in 1956, poliomyelitis appears to get a sporadic development. Consequently, it has not been a major medical concern. In 1982, 5 cases of paralytic manifestations due to a polio virus of type 1 underlined the relationship between this reappearance of the disease, some neglecting in mass vaccination and some deficiency in sanitary conditions of the surroundings. A serologic monitoring, complementary to that survey, has been conducted up to 1984. It has shown that, in a number of zones of the territory, a natural immunization has appeared quickly. This immunization is of the same type that in some underdeveloped tropical countries: at 6, 93,3% of the children present protective antibodies against 1 type of virus, 40% against 2 types and 6,7% against the 3 types. Vaccination with non-active vaccine, adopted because the risks of interference linked to the frequency of excretion of the enteroviruses, is efficient. After a primo-vaccination followed by a booster dose one year later, sero-conversion ranges from 95,3% to 100% for type 1, 83,3% to 96,5% for type 2, 75% to 84,9% for type 3. On the other hand, sero-conversion observed one month after the second vaccination appeared to be unsatisfactory to lighter the vaccinal time-table.
mesh_terms: D000293:Adolescent; D000914:Antibodies, Viral / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D003168:Complement Fixation Tests; D005260:Female; D006801:Humans; D007114:Immunization; D007223:Infant; D008297:Male; D009500:Neutralization Tests; D009510:New Caledonia; D011051:Poliomyelitis / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D017955:Poliovirus / Q000276:immunology; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage; D014611:Vaccination
chemical_list: D000914:Antibodies, Viral; D011054:Poliovirus Vaccine, Inactivated
vernacular_title: La poliomyélite en Nouvelle-Calédonie: données épidémiologiques, séroconversions post vaccinales, stratégie prophylactique.